Header Logo

Connection

GEORGE CHOLANKERIL to Non-alcoholic Fatty Liver Disease

Back to Details
This is a "connection" page, showing publications GEORGE CHOLANKERIL has written about Non-alcoholic Fatty Liver Disease.
GEORGE CHOLANKERIL
Connection Strength
7.974
Non-alcoholic Fatty Liver Disease
  1. Reply to: "Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea". J Hepatol. 2024 May; 80(5):e218-e219.
    View in: PubMed
    Score: 0.611
  2. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023 03; 78(3):493-500.
    View in: PubMed
    Score: 0.562
  3. Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2023 02; 43(1):89-99.
    View in: PubMed
    Score: 0.558
  4. The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease. Curr Opin Infect Dis. 2021 10 01; 34(5):477-482.
    View in: PubMed
    Score: 0.520
  5. NAFLD and HCC: Time to Bridge the Gap. Hepatology. 2021 11; 74(5):2336-2338.
    View in: PubMed
    Score: 0.517
  6. Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. Dig Dis Sci. 2017 10; 62(10):2915-2922.
    View in: PubMed
    Score: 0.389
  7. Nonalcoholic Fatty Liver Disease: Epidemiology, Natural History, and Diagnostic Challenges. Hepatology. 2016 09; 64(3):954.
    View in: PubMed
    Score: 0.363
  8. Steatotic liver disease-associated all-cause/cause-specific mortality in the United States. Aliment Pharmacol Ther. 2024 07; 60(1):33-42.
    View in: PubMed
    Score: 0.155
  9. Impact of the COVID-19 pandemic on hospitalizations with hepatocellular carcinoma in the United States. Expert Rev Gastroenterol Hepatol. 2024 Jan-Feb; 18(1-3):113-119.
    View in: PubMed
    Score: 0.153
  10. Exposure to Agent Orange and Hepatocellular Carcinoma Among US Military Personnel. JAMA Netw Open. 2023 12 01; 6(12):e2346380.
    View in: PubMed
    Score: 0.151
  11. Endogenous sex hormones and nonalcoholic fatty liver disease in US adults. Liver Int. 2024 Feb; 44(2):460-471.
    View in: PubMed
    Score: 0.151
  12. Predictive Algorithm for Hepatic Steatosis Detection Using Elastography Data in the Veterans Affairs Electronic Health Records. Dig Dis Sci. 2023 12; 68(12):4474-4484.
    View in: PubMed
    Score: 0.150
  13. Chronic liver disease-related mortality during the COVID-19 pandemic. Eur J Intern Med. 2023 12; 118:129-132.
    View in: PubMed
    Score: 0.149
  14. Depression in nonalcoholic fatty liver disease and all-cause/cause-specific mortality. Eur J Clin Invest. 2024 Jan; 54(1):e14087.
    View in: PubMed
    Score: 0.148
  15. Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis. J Affect Disord. 2023 05 15; 329:184-191.
    View in: PubMed
    Score: 0.143
  16. Telehealth interventions in patients with chronic liver diseases: A systematic review. Hepatology. 2023 07 01; 78(1):179-194.
    View in: PubMed
    Score: 0.142
  17. Muscle strength in non-alcoholic fatty liver disease and all-cause and cause-specific mortality. Liver Int. 2023 02; 43(2):513-516.
    View in: PubMed
    Score: 0.141
  18. Chronic liver disease-related mortality in diabetes before and during the COVID-19 in the United States. Dig Liver Dis. 2023 01; 55(1):3-10.
    View in: PubMed
    Score: 0.139
  19. Changing trends in aetiology-based hospitalizations with end-stage liver disease in the United States from 2016 to 2019. Liver Int. 2022 11; 42(11):2390-2395.
    View in: PubMed
    Score: 0.138
  20. Trends in Etiology-based Mortality From Chronic Liver Disease Before and During COVID-19 Pandemic in the United States. Clin Gastroenterol Hepatol. 2022 10; 20(10):2307-2316.e3.
    View in: PubMed
    Score: 0.137
  21. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC). Dig Dis Sci. 2023 03; 68(3):1060-1070.
    View in: PubMed
    Score: 0.137
  22. Gallstone Disease and Its Association With Nonalcoholic Fatty Liver Disease, All-Cause and Cause-Specific Mortality. Clin Gastroenterol Hepatol. 2023 04; 21(4):940-948.e2.
    View in: PubMed
    Score: 0.136
  23. Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease: A Review of the Literature With Recommendations. J Clin Gastroenterol. 2021 10 01; 55(9):747-756.
    View in: PubMed
    Score: 0.130
  24. Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA. Hepatology. 2021 12; 74(6):3316-3329.
    View in: PubMed
    Score: 0.130
  25. Physical Activity Is Associated With Nonalcoholic Fatty Liver Disease and Significant Fibrosis Measured by FibroScan. Clin Gastroenterol Hepatol. 2022 06; 20(6):e1438-e1455.
    View in: PubMed
    Score: 0.128
  26. Sarcopenia in nonalcoholic fatty liver disease and all-cause and cause-specific mortality in the United States. Liver Int. 2021 08; 41(8):1832-1840.
    View in: PubMed
    Score: 0.125
  27. Prevalence of Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis Among US Adults with Prediabetes and Diabetes, NHANES 2017-2018. J Gen Intern Med. 2022 01; 37(1):261-263.
    View in: PubMed
    Score: 0.125
  28. Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease. Hepatology. 2020 11; 72(5):1556-1568.
    View in: PubMed
    Score: 0.122
  29. Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality. Am J Gastroenterol. 2020 09; 115(9):1496-1504.
    View in: PubMed
    Score: 0.121
  30. Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018. Clin Gastroenterol Hepatol. 2021 07; 19(7):1499-1501.e2.
    View in: PubMed
    Score: 0.120
  31. Physical Activity, Measured Objectively, Is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2021 06; 19(6):1240-1247.e5.
    View in: PubMed
    Score: 0.120
  32. Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol. 2020 04; 11(4):e00165.
    View in: PubMed
    Score: 0.117
  33. Diet quality and its association with nonalcoholic fatty liver disease and all-cause and cause-specific mortality. Liver Int. 2020 04; 40(4):815-824.
    View in: PubMed
    Score: 0.116
  34. Depression is associated with non-alcoholic fatty liver disease among adults in the United States. Aliment Pharmacol Ther. 2019 09; 50(5):590-598.
    View in: PubMed
    Score: 0.112
  35. Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017. Gastroenterology. 2019 10; 157(4):1055-1066.e11.
    View in: PubMed
    Score: 0.111
  36. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. Liver Int. 2019 09; 39(9):1661-1671.
    View in: PubMed
    Score: 0.111
  37. Elevated urinary bisphenol A levels are associated with non-alcoholic fatty liver disease among adults in the United States. Liver Int. 2019 07; 39(7):1335-1342.
    View in: PubMed
    Score: 0.110
  38. Association of Pretransplant Renal Function With Liver Graft and Patient Survival After Liver Transplantation in Patients With Nonalcoholic Steatohepatitis. Liver Transpl. 2019 03; 25(3):399-410.
    View in: PubMed
    Score: 0.109
  39. Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016. Hepatol Int. 2019 Mar; 13(2):205-213.
    View in: PubMed
    Score: 0.108
  40. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology. 2018 10; 155(4):1154-1163.e3.
    View in: PubMed
    Score: 0.105
  41. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017 Dec 21; 23(47):8263-8276.
    View in: PubMed
    Score: 0.100
  42. Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis. Clin Mol Hepatol. 2024 Jul; 30(3):436-448.
    View in: PubMed
    Score: 0.039
  43. Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2019 02; 31(2):149-156.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.